Stock of the Day

Alnylam Pharmaceuticals (ALNY)

$240.69

+$3.59 (+1.5%)

Market Cap: $31.73B

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

• The stock has shown significant growth potential, with a recent price range indicating a high of around $495.55, suggesting strong market interest and investor confidence.
• Alnylam Pharmaceuticals, Inc. reported impressive quarterly earnings, exceeding analysts' expectations, which reflects the company's robust financial health and operational efficiency.
• The company has a high return on equity, indicating effective management and the ability to generate profits from shareholders' investments.
• With a market capitalization of approximately $30.59 billion, Alnylam Pharmaceuticals, Inc. is positioned as a major player in the biopharmaceutical sector, attracting institutional investors.
• The company has demonstrated a strong revenue growth of nearly 67% compared to the same quarter last year, showcasing its ability to expand and capture market share.

Alnylam Pharmaceuticals Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

• The stock has a relatively high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
• Despite recent revenue growth, the company did not meet its revenue estimates for the last quarter, which could raise concerns about future performance.
• Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.75, suggesting that it relies on debt financing, which could pose risks if market conditions change.
• Insider selling activity, such as the recent sale of shares by a director, may signal a lack of confidence in the stock's short-term performance.
• The stock's beta of 0.30 indicates lower volatility compared to the market, which may limit potential gains during bullish market conditions.

Recent News

• Alnylam Presents New Data Validating AMVUTTRA In ATTR; Provides Updates On Zilebesiran (rttnews.com)
• Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (msn.com)
• Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings (businesswire.com)
• Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Amgen (AMGN) (theglobeandmail.com)
• Alnylam stock drops on rival heart trial: Why analysts see core business safe (finance.yahoo.com)
• ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc. (globenewswire.com)